Bevacizumab treatment for newly diagnosed glioblastoma: Systematic review and meta-analysis of clinical trials
Bevacizumab Plus Standard Chemotherapy Improves Survival in Mesothelioma - The ASCO Post
Impact of Bevacizumab-containing Primary Treatment on Outcome of Recurrent Ovarian Cancer: An Italian Study | Anticancer Research
Avastin® (bevacizumab) Clinical Trials | CC Treatment
Bevacizumab Misses Mark in Untreated Metastatic Bladder Cancer | MedPage Today
Cancers | Free Full-Text | Bevacizumab in First-Line Chemotherapy Improves Progression-Free Survival for Advanced Ovarian Clear Cell Carcinoma
Panitumumab beats bevacizumab in RAS wildtype left-sided metastatic colorectal cancer - Medical Conferences
Overall survival according to the addition of bevacizumab to first-line... | Download Scientific Diagram
Evidence for improved survival with bevacizumab treatment in recurrent high-grade gliomas: a retrospective study with (“pseudo-randomized”) treatment allocation by the health insurance provider | SpringerLink
Overall survival for patients randomized to receive (A) bevacizumab (n... | Download Scientific Diagram
Landmark OS for HCC, updated IMbrave150 data - Medical Conferences
Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study - ScienceDirect
Adding Olaparib to Bevacizumab Maintenance Improves Progression
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3 | British Journal of
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial | British Journal of Cancer
When more is better: bevacizumab treatment for patients with ovarian cancer
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study - The
Figure 3 from Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. | Semantic Scholar
Bevacizumab and chemotherapy for recurrent glioblastoma | Neurology
IMpower150 Clinical Trial Results | TECENTRIQ® (atezolizumab)
Overall survival and time to treatment failure for patients eligible... | Download Scientific Diagram
A Phase 3 Trial of Bevacizumab in Ovarian Cancer | NEJM
Improved Survival with Bevacizumab in Advanced Cervical Cancer | NEJM
Avastin® (bevacizumab) Clinical Trials | NSCLC Treatment
Servier and Taiho Oncology Present Overall Survival Data for Trifluridine/Tipiracil (LONSURF®) In Combination With Bevacizumab in Patients With Refractory Metastatic Colorectal Cancer at 2023 ASCO Gastrointestinal Cancers Symposium
Avastin® (bevacizumab) Clinical Trials | MRCC Treatment
Systemic administration of bevacizumab prolongs survival in an in vivo model of platinum pre-treated ovarian cancer
